PLACEBO CONTROLLED TRIAL

New treatment discovered for rare eye disease may prevent blindness

Patients received the drug intravenously once every week for three weeks over a 21-week period. Results showed that patients who were administered teprotumumab experienced effective response in two doses or six weeks of administration. After 24 weeks, the study showed 83 per cent of people on the drug had measurable reduction in eye bulge versus ten per cent of those on a placebo.